Estrogen receptor negative Trials in Houston, United States
Conditions / Estrogen receptor negative / Houston, United States
Research into Estrogen receptor negative spans multiple therapeutic approaches and trial phases.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | COMPLETED | PHASE2 |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02945579 | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | RECRUITING | NA |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03609021 | Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502 | TERMINATED | — |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | TERMINATED | PHASE1/PHASE2 |
| NCT02744053 | DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | TERMINATED | PHASE2 |
| NCT03291938 | IACS-010759 in Advanced Cancers | COMPLETED | PHASE1 |